Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 2Phase 2 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 505Urinary Bladder Neoplasms 139Carcinoma, Renal Cell 117Neoplasms 67Kidney Neoplasms 53Non-Muscle Invasive Bladder Neoplasms 43Neoplasm Metastasis 38Carcinoma, Transitional Cell 38Breast Neoplasms 30Testicular Neoplasms 28Recurrence 20Wilms Tumor 18Parkinson Disease 4, Autosomal Dominant Lewy Body 14Pain 13Ovarian Neoplasms 13Urologic Neoplasms 12Testicular Germ Cell Tumor 12Teratoma 12Seminoma 12Multiple Myeloma 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Carcinoma 11Urogenital Neoplasms 10Neuroblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Prostate Cancer Recurrent × Genitourinary × Clear all
NCT06922929 2025-04-11

A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

Yunhe Pharmaceutical (Tianjin) Co., Ltd

Phase 3 Not yet recruiting
110 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04734184 2021-02-02

Python

Curium PET France

Phase 3 Unknown
217 enrolled
Genitourinary

Prostate Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡